Market Place
Sourcing Support
Genethon Highlights Atamyo`s Gene Therapy, LGMD Progress
19 Jun 2025 //
BUSINESSWIRE
FDA Clears IND for ATA-200 Gene Therapy for LGMD2C/R5
12 Nov 2024 //
BUSINESSWIRE
Atamyo Therapeutics Celebrates LGMD Awareness Day With Updates
30 Sep 2024 //
BUSINESSWIRE
Atamyo Therapeutics To Present At 6 Upcoming Conferences in US
16 Sep 2024 //
BUSINESSWIRE
Dion Foundation and Atamyo Partner to Expand US Trial of ATA-200 for LGMD2C/R5
04 Sep 2024 //
BUSINESSWIRE
Genethon`s DMD Gene Therapy, Atamyo`s LGMD, Cardiomyopathy Advances
03 Jun 2024 //
BUSINESSWIRE
Atamyo Obtains RA in Europe for Trial to Treat Limb-Girdle MD Type 2C/R5
26 Mar 2024 //
BUSINESSWIRE
Atamyo Therapeutics Announces participation in Conferences
29 Sep 2023 //
BUSINESSWIRE
ATA-200 to Treat Limb-Girdle Muscular Dystrophy , Reaches Key Milestones
19 Sep 2023 //
BUSINESSWIRE
IND for ATA-100, a Gene Therapy for Treatment of Limb-Girdle Muscular Dystrophy
06 Sep 2023 //
BUSINESSWIRE
Gene Therapy Pioneer Roger Hajjar Joins Atamyo Therapeutics Board of Directors
24 Jul 2023 //
BUSINESSWIRE
Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
27 Sep 2022 //
CLINICALTRIALSARENA
Atamyo Therapeutics Announces First Patient Dosed with ATA-100
26 Sep 2022 //
BUSINESSWIRE
Atamyo Announces Significant Milestones for ATA-100 and ATA-200
16 May 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.